See more : Sempra (0L5A.L) Income Statement Analysis – Financial Results
Complete financial analysis of Scopus BioPharma Inc. (SCPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Scopus BioPharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Shanghai Weaver Network Co., Ltd. (603039.SS) Income Statement Analysis – Financial Results
- Mirasol Resources Ltd. (0V7B.L) Income Statement Analysis – Financial Results
- Hamayuu Co.,Ltd. (7682.T) Income Statement Analysis – Financial Results
- PT Net Visi Media Tbk (NETV.JK) Income Statement Analysis – Financial Results
- Carvana Co. (CVNA) Income Statement Analysis – Financial Results
Scopus BioPharma Inc. (SCPS)
About Scopus BioPharma Inc.
Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases. The company lead development programs are immuno-oncology gene therapy for the treatment of various cancers. It offers Duet Platform, a CpG signal transducer and activator of transcription 3 (STAT3) inhibitors; and MRI-1867, rationally designed, orally available, dual-action, hybrid, and small molecule that is an inverse agonist of the endocannabinoid system/cannabinoid receptor 1, as well as an inhibitor of inducible nitric oxide synthase. Scopus BioPharma Inc. has strategic partnerships with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem for its lead development and other programs. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.68M | 15.02M | 7.42M | 463.11K | 277.54K |
| General & Administrative | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.03M | 12.61M | 2.73M | 2.23M | 408.43K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Cost & Expenses | 11.71M | 27.63M | 10.16M | 2.69M | 685.96K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 774.68K | 706.45K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.73K | 1.50K | 1.44K | 664.00 | 161.14K |
| EBITDA | -11.71M | -27.63M | -10.15M | -2.69M | -685.96K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -11.71M | -27.63M | -10.16M | -2.69M | -685.96K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | 681.21K | -706.45K | 0.00 | 0.00 |
| Income Before Tax | -11.71M | -26.95M | -10.86M | -2.69M | -685.96K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -105.05K | 774.68K | 706.45K | 1.00 | -847.11K |
| Net Income | -11.61M | -27.73M | -11.57M | -2.69M | -685.96K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| EPS Diluted | -0.55 | -1.61 | -0.87 | -0.18 | -0.05 |
| Weighted Avg Shares Out | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
| Weighted Avg Shares Out (Dil) | 21.09M | 17.25M | 13.36M | 14.98M | 14.98M |
Scopus BioPharma to Reschedule 2021 Annual Meeting of Shareholders
SCPS Stock Price: 71.98% Increase Explanation
Why Scopus BioPharma's Stock Is Surging Today
Why Scopus, NGM Biopharma and Taiwan Liposome Are Moving Today
Why Scopus BioPharma Stock More Than Double Today?
Here's why Scopus BioPharma gained 200% on Monday
SCPS Stock Price: Over 200% Increase Explanation
Scopus BioPharma Announces FDA Approval of IND Application for Lead Drug Candidate
Scopus BioPharma Announces Closing of Underwriters' Over-Allotment Option in Full
Underwriters Exercise Over-Allotment Option in Full, Brings Total Follow-On Public Offering Proceeds to $10.35 Million
Source: https://incomestatements.info
Category: Stock Reports